Serious adverse events ‐ not reported · farmworkers, soldiers, and people in endemic areas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).
1 finding from 1 review
RR 0.27 [0.02, 3.74]
1 study · 5 participants
Very low
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Serious adverse events/death: medium‐term outcomes · rehabilitation (medium‐term outcomes)
It is very uncertain whether summary of findings table ‐ More time changes serious adverse events/death: medium‐term outcomes compared with less time (very low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Adverse events of any severity or seriousness · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review